The FDA approved Lenacapavir, the first twice-a-year injection to prevent HIV, marking a historic step in public health. Mistr, an LGBTQIA+-owned platform known for making sexual healthcare accessible ...
On June 18, the U.S. Food and Drug Administration (FDA) approved the first medicine to prevent HIV that only has to be taken twice a year. People who are at high risk for HIV can now take the ...
A newly approved HIV medication provides near-total protection against infection with just two injections a year. It's called Lenacapavir. But the high price of the drug could limit its reach. A newly ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Though Gilead Sciences made waves last June with a landmark FDA approval for its twice-yearly HIV preventive Yeztugo (lenacapavir), the first-in-class drug had previously been used as a long-acting ...
It’s possible to produce a generic version of lenacapavir, a twice-yearly antiretroviral injection that both prevents and treats HIV, for as little as $25 per patient per year, according to a study ...
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, lenacapavir, as a tool in their efforts to fight HIV infections – especially for ...
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The double-blind trial evaluated the treatment ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has been awarded the prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product for Yeztugo® (lenacapavir), the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results